Survey and Monitoring of the prevalence of MRSA, MSSA and CNS of patients with elective orthopedic and cardiovascular interventions

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004261

Enrollment

1500

Registered

2012-07-24

Start date

2012-04-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U80.0

Interventions

Group 1: Patients with elective orthopedic and cardiovascular interventions will be screen with swabs from the groin, nose and throat swabs and operated area before the interventions and immediately b

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: • aged 18 to 80 years • elective surgical procedures in the hip and knee replacements, artificial heart valves and cardiac pacing and use of cardiovascular stent implantation • The ability to understand the scope and significance of the trial and take part in the willingness and ability of the necessary follow-up • existence of a written consent form

Exclusion criteria

Exclusion criteria: • presence of a tumor disease • Known allergy to used materials • nursing and pregnant women and those women planning to become pregnant during the trail period • non-availability for the duration of the trial

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is the analysis of the microbial spectrum and the prevalence of MRSA, MSSA and CNS in microbiological swabs of the skin, nose and throat in patients with elective surgery in the hip and knee replacements, artificial heart valves and cardiac pacing applications, as well as cardiovascular stent implantation. The patients will be screen with swabs from the groin, nose and throat swabs and operated area before the interventions and immediately before discharge. The will be tested for MRSA and KNS (microbiological culture methods). After a 12-month follow-up the patients will be ask by telephone to a questionnaire on infection-procedure in the operated area.	—

Measure

Time frame

The primary outcome measure is the analysis of the microbial spectrum and the prevalence of MRSA, MSSA and CNS in microbiological swabs of the skin, nose and throat in patients with elective surgery in the hip and knee replacements, artificial heart valves and cardiac pacing applications, as well as cardiovascular stent implantation. The patients will be screen with swabs from the groin, nose and throat swabs and operated area before the interventions and immediately before discharge. The will be tested for MRSA and KNS (microbiological culture methods). After a 12-month follow-up the patients will be ask by telephone to a questionnaire on infection-procedure in the operated area.

—

Secondary

Measure	Time frame
The secondary objective criterion is the detection frequency of intervention-associated infections within the follow-up of 12 months.	—

Countries

Germany

Contacts

Public ContactSarah Zaatreh

Forschungslabor für Biomechanik und Implantattechnologie Orthopädische Klinik und Poliklinik, Universitätsmedizin Rostock

sarah.zaatreh@med.uni-rostock.de03814949374

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026